Medindia

X

Amgen Oncology Data to be Presented at ASCO Annual Meeting

Thursday, May 19, 2011 General News J E 4
Advertisement

SELECTED XGEVA ABSTRACTS

  • Effect of denosumab vs. zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain

(Abstract 4533)  Poster Discussion on Saturday, June 4, 2:00 p.m. - 6:00 p.m., E450a

  • Prevalence of recognized bone metastases in the U.S. adult population

(Abstract 1534) Poster on Saturday, June 4, 2:00 p.m. - 6:00 p.m., Hall A

  • Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study

(Abstract 10034) Poster on Sunday, June 5, 8:00 a.m. - 12:00 p.m., Hall A

  • Effects of denosumab on pain reduction in giant cell tumor of bone (GCTB): interim phase II study results

(Abstract 10037) Poster on Sunday, June 5, 8:00 a.m. - 12:00 p.m., Hall A

  • A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE)

(Abstract TPS152) Poster on Monday, June 6, 8:00 a.m. - 12:00 p.m., Hall A

  • A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates

(Abstract TPS245) Poster on Monday, June 6, 8:00 a.m. - 12:00 p.m., Hall A

SELECTED VECTIBIX ABSTRACTS

  • Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC)

(Abstract 3510) Oral Presentation on Saturday, June 4, 1:00 p.m. - 4:00 p.m., Hall D1

  • Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS)

(Abstract 3567) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A

  • Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)

(Abstract 3617) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A

  • Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181

(Abstract 3574) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A

  • The relationship between quality of life (QOL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314

(Abstract 3634) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A

  • Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC)

(Abstract 3530) Poster Discussion on Monday, June 6, 8:00 a.m. - 12:00 p.m., E450b

SELECTED ARANESP® (darbepoetin alfa) ABSTRACTS

  • Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study

(Investigator Sponsored Abstract 9048) Saturday, June 4, 2:00 p.m. - 6:00 p.m., Hall A

SELECTED PIPELINE ABSTRACTS

  • A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses

(Abstract 3500) Oral Presentation on Saturday, June 4, 4:30 p.m. - 6:00 p.m., Hall D1

  • Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) with ganitumab (GAN, AMG 479) or placebo (P) in combination with gemcitabine (G)

(Abstract 4041) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A

  • Exposure-response (E-R) analysis to facilitate phase III dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC)

(Abstract 4049) Poster on Saturday, June 4, 8:00 a.m. - 12:00 p.m., Hall A

  • A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)

(Abstract 544) Poster on Monday, June 6, 1:00 p.m. - 5:00 p.m., Hall A

  • An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC)

(Abstract LBA7512) Poster Discussion on Monday, June 6, 2:00 p.m. - 6:00 p.m., E450a

For the latest updates on Amgen's presence at ASCO and other Amgen news, follow us on Twitter @Amgen.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New Study Finds That 10% of Cancer Patients Abando...
S
Dendreon Announces Presentation of PROVENGE Data a...